Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12471594 | 0.91 | ALDH1A1 (0.55) | ALDH1A1GAATSHRPOLBESR2 | |
| SCHEMBL7632848 | 0.88 | TSHR (0.44) | ALDH1A1GAATSHRPOLBKDM4E | |
| SCHEMBL6694368 | 0.77 | NPC1 (0.44) | ALDH1A1TSHRPOLBKDM4ENPC1 | |
| SCHEMBL3240558 | 0.77 | TSHR (0.42) | ALDH1A1GAATSHRPOLBKDM4E | |
| SCHEMBL9271980 | 0.77 | MAPT (0.47) | ALDH1A1GAATSHRPOLBKDM4E | |
| SCHEMBL5434824 | 0.77 | MAPT (0.44) | ALDH1A1TSHRPOLBKDM4ENPC1 | |
| SCHEMBL2564135 | 0.77 | MAPT (0.47) | ALDH1A1TSHRPOLBKDM4ENPC1 | |
| SCHEMBL5909370 | 0.77 | POLB (0.50) | ALDH1A1GAATSHRPOLBKDM4E | |
| SCHEMBL8064824 | 0.77 | TSHR (0.58) | ALDH1A1GAATSHRPOLBKDM4E | |
| SCHEMBL21280037 | 0.75 | TSHR (0.45) | ALDH1A1TSHRESR2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261201-A1 | A METHOD OF PROVIDING HIGH SPF TO A TOPICAL SURFACE OF A BODY | CONOPCO, INC., D/B/A UNILEVER (US) | 2024-08-08 | — | — | US | claimed |
| CN-101360715-A | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer's disease, neurodegeneration and dementia | ASTRAZENECA AB (SE) | 2009-02-04 | — | — | CN | claimed |
| JP-9328411-A | — | — | None | — | — | JP | disclosed |
| EP-4661834-A1 | A PERSONAL CARE COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-12-17 | — | — | EP | disclosed |
| EP-4615989-A1 | METHOD FOR PRODUCING EPIGALLOCATECHIN GALLATE MONOGLUCOSIDE | Givaudan SA (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4604907-A1 | A METHOD OF PROVIDING HIGH SPF TO A TOPICAL SURFACE OF A BODY | Unilever IP Holdings B.V. (NL) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025098792-A1 | USE OF A SKIN BENEFIT AGENT IN RESTORING SKIN'S BARRIER FUNCTION | UNILEVER IP HOLDINGS B.V. (NL) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025098825-A1 | A PERSONAL CARE COMPOSITION AND A METHOD OF TREATING SKIN | UNILEVER IP HOLDINGS B.V. (NL) | 2025-05-15 | — | — | WO | disclosed |
| WO-2025098793-A1 | USE OF A SKIN BENEFIT AGENT IN BOOSTING SKIN'S NIGHT REPAIR FUNCTION | UNILEVER IP HOLDINGS B.V. (NL) | 2025-05-15 | — | — | WO | disclosed |
| CN-119925222-A | Blue-light-resistant skin care composition containing anthrus extract and application thereof | 天津尚美化妆品有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119656079-A | Blue-light-resistant skin care composition containing anthrus extract and application thereof | 天津尚美化妆品有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-5770731-A | PROTECTING GROUPS, ANTIBODY DIRECTED ENZYME/PRODRUG THERAPY, ANTICARCINOGENIC AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| US-5728868-A | Prodrugs of protein tyrosine kinase inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
| JP-H09328411-A | SKIN LOTION | MIKIMOTO PHARMACEUT CO LTD | 1997-12-22 | — | — | JP | disclosed |
| EP-0708660-A1 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
| US-5393776-A | Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| WO-1995002420-A2 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1995-01-26 | — | — | WO | disclosed |
| EP-0571928-A1 | Acyclic Tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1993-12-01 | — | — | EP | disclosed |
| EP-0476493-A1 | Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia | Bristol-Myers Squibb Company (US) | 1992-03-25 | — | — | EP | disclosed |
| US-4661611-A | PHOTORESISTS | FUJI PHOTO FILM CO., LTD. (JP) | 1987-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261201-A1 | A METHOD OF PROVIDING HIGH SPF TO A TOPICAL SURFACE OF A BODY | CUTA, ERCC4, FIBP | ALDH1A1 919/4885GAA 1436/4885TSHR 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.